Geode Capital Management
VRPX

Geode Capital Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Geode Capital Management’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,676
Closed -$15.5K – 4578
2024
Q4 		$15.5K Buy
1,676
+557
+50% +$7.4K ﹤0.01% 4405
2024
Q3 		$19.4K Buy
+1,119
New +$27.8K ﹤0.01% 4397
2024
Q1 		– Sell
-256
Closed -$20.2K – 4678
2023
Q4 		$20.2K Hold
256
– – ﹤0.01% 4513
2023
Q3 		$51.2K Sell
256
-8
-3% -$1.76K ﹤0.01% 4415
2023
Q2 		$72K Hold
264
– – ﹤0.01% 4431
2023
Q1 		$51.6K Hold
264
– – ﹤0.01% 4510
2022
Q4 		$41K Sell
264
-1
-0.4% -$228 ﹤0.01% 4649
2022
Q3 		$78K Hold
265
– – ﹤0.01% 4663
2022
Q2 		$111K Buy
265
+13
+5% +$5.33K ﹤0.01% 4551
2022
Q1 		$139K Buy
252
+61
+32% +$35.6K ﹤0.01% 4535
2021
Q4 		$163K Buy
191
+151
+378% +$156K ﹤0.01% 4567
2021
Q3 		$48K Buy
+40
New +$83.8K ﹤0.01% 4791

Other funds holding VRPX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return

Geode Capital Management's VRPX Position: Q1 2025 in Review

Geode Capital Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2025, closing a stake of 1,676 shares — an estimated $15.5K sold.

Geode Capital Management first reported a position in VRPX in Q3 2021 and held it in 12 quarters. The position peaked at $163K in Q4 2021. 7 funds tracked by Wall St. Rank hold VRPX as of Q1 2025.

  • Geode Capital Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 1,676 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $15.5K.
  • Geode Capital Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Geode Capital Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $163K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.